Louisiana Lawsuit Challenges FDA Dispensing Rules for Mifepristone
The latest in this situation
How it started
What happened
A lawsuit filed by Louisiana challenges federal dispensing rules for abortion medication, arguing that remote prescribing and mailing undermine the state's abortion ban. The FDA is conducting a review of mifepristone, which examines whether patients must again obtain the drug in person. The FDA expects to receive study results by mid-December 2026 and complete its review by March 2027.
From rawstory.com
Why it matters
The review, which is part of efforts by the Donald Trump administration, could lead to changes in the Mifepristone REMS Program. The FDA's decision on dispensing rules is being challenged by Louisiana, which seeks to enforce its state abortion ban.
From rawstory.com
Who's involved
- FDAThe regulatory agency reviewing mifepristone and dispensing rules.
- Donald TrumpThe administration whose efforts are laying groundwork for a potential crackdown on abortion medication.
- LouisianaThe state filing a lawsuit challenging federal drug dispensing rules.
How it developed
Newest first. Tap a step to see who reported it.- Louisiana closed a regulatory loophole, and researchers at Yale School of Medicine tested products.Sub-event
Louisiana lawsuit challenges dispensing rules amid Trump administration crackdown efforts.1 source
Keep exploring
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Louisiana
state of the United States of America